EMA/231237/2021

European Medicines Agency decision

P/0179/2021

of 23 April 2021

on the acceptance of a modification of an agreed paediatric investigation plan for highly purified single-stranded, 5'-capped mRNA encoding full-length SARS-CoV-2 spike protein (BNT162b2) (Comirnaty), (EMEA-002861-PIP02-20-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0179/2021

of 23 April 2021

on the acceptance of a modification of an agreed paediatric investigation plan for highly purified single-stranded, 5'-capped mRNA encoding full-length SARS-CoV-2 spike protein (BNT162b2) (Comirnaty), (EMEA-002861-PIP02-20-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0480/2020 issued on 27 November 2020,

Having regard to the application submitted by BioNTech Manufacturing GmbH on 25 March 2021 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 April 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for highly purified single-stranded, 5'-capped mRNA encoding full-length SARS-CoV-2 spike protein (BNT162b2) (Comirnaty), concentrate for dispersion for injection, intramuscular use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to BioNTech Manufacturing GmbH, An der Goldgrube 12, 55131 - Mainz, Germany.

EMA/PDCO/194007/2021 Corr
Amsterdam, 9 April 2021

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002861-PIP02-20-M01

Scope of the application

Active substance(s):

Highly purified single-stranded, 5'-capped mRNA encoding full-length SARS-CoV-2 spike protein (BNT162b2)

Invented name:

Comirnaty

Condition(s):

Prevention of Coronavirus disease 2019 (COVID-19)

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Concentrate for dispersion for injection

Route(s) of administration:

Intramuscular use

Name/corporate name of the PIP applicant:

BioNTech Manufacturing GmbH

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, BioNTech Manufacturing GmbH submitted to the European Medicines Agency on 25 March 2021 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0480/2020 issued on 27 November 2020.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 6 April 2021.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Prevention of Coronavirus disease 2019 (COVID-19)

2.1.1. Indication(s) targeted by the PIP

Prevention of Coronavirus disease 2019 (COVID-19)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Concentrate for solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	0	Not applicable
Clinical studies	4	**Study 1 (C4591001)** Double blind dose-finding study of safety, tolerability, and immunogenicity of 2 different SARS-CoV-2 vaccine candidates (adults only) (part 1) and placebo-controlled efficacy, safety and immunogenicity study of highly purified single-stranded, 5'-capped mRNA encoding full-length SARS-CoV-2 spike protein (BNT162b2) in adolescents from 12 years to less than 18 years of age (and adults) (part 2) for prevention of COVID-19 **Study 2 (C4591007)** Double blind, controlled, dose-finding safety, tolerability, and immunogenicity study of BNT162b2 in children and adolescents from 6 months to less than 12 years of age for prevention of COVID-19 **Study 3** Open, controlled, dose-finding, safety and immunogenicity study of BNT162b2 in children from birth to less than 6 months of age for prevention of COVID-19

		Study 4 Open label, uncontrolled, safety and immunogenicity study of BNT162b2 in immunocompromised children from birth to less than 18 years of age for prevention of COVID-19
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By July 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition and authorised indication:

1. Prevention of COVID-19

Authorised indication(s):

- Comirnaty is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older.

Authorised pharmaceutical form(s):

Concentrate for dispersion for injection

Authorised route(s) of administration:

Intramuscular route